TY - JOUR
T1 - The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing
AU - Ambrose, C. S.
AU - Dubovsky, F.
AU - Yi, T.
AU - Belshe, R. B.
AU - Ashkenazi, S.
N1 - Funding Information:
Acknowledgments This analysis was supported by MedImmune, LLC. Editorial assistance was provided by Complete Healthcare Communications, Inc., Chadds Ford, PA, USA, and funded by MedI-mmune. Drs. Ambrose, Dubovsky, and Yi are employees of MedImmune. Dr. Belshe has served on advisory boards and as a consultant for MedImmune. Drs. Belshe and Ashkenazi have received research support and speaker compensation from MedImmune.
PY - 2012/10
Y1 - 2012/10
N2 - In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p
AB - In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p
UR - https://www.scopus.com/pages/publications/84869103013
U2 - 10.1007/s10096-012-1595-9
DO - 10.1007/s10096-012-1595-9
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 22410646
AN - SCOPUS:84869103013
SN - 0934-9723
VL - 31
SP - 2549
EP - 2557
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
IS - 10
ER -